Andrew Dudum, the Chief Executive Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has sold a significant portion of his stock in the company, totaling over $4.8 million. The transactions, which took place on September 3, 2024, were disclosed in a recent filing with the Securities and Exchange Commission.
The CEO sold 188,888 shares at an average weighted price of approximately $14.5594, and another 144,444 shares at an average weighted price of around $14.5027. The shares were sold at varying prices within the ranges of $14.42 to $14.71 and $14.305 to $14.70, respectively. These sales resulted in a total transaction value of $4,844,923 for the sold shares.
In addition to the sales, Dudum also exercised options to acquire 188,888 shares of Class A Common Stock at a price of $2.43 per share, which amounted to a total of $458,997. This transaction was made under a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying and selling securities and is typically used to avoid accusations of insider trading.
Following the sales, Dudum's direct ownership in the company decreased, while indirect ownership through various trusts remained substantial. The CEO still holds a significant number of shares indirectly, including through trusts set up for estate planning purposes.
Investors often monitor insider transactions for insights into how executives perceive the value of their company stock. However, such sales can also be part of regular financial planning and diversification strategies by company insiders.
For more detailed information on the transactions, including the exact number of shares sold at each separate price, the filing indicates that the CEO will provide full information upon request by the Commission, the issuer, or a security holder of the issuer.
In other recent news, Hims & Hers Health, Inc. has been the focus of varied analyst attention, following robust growth in its second quarter. The telehealth company saw a 52% year-over-year increase in revenue, reaching $316 million, and reported an adjusted EBITDA of $39 million. Citi maintained its neutral rating on the company, while Needham initiated coverage with a buy rating. Conversely, Jefferies lowered its price target to $18, citing a slower progression towards higher profit margins, while Deutsche Bank (ETR:DBKGn) raised its target to $23, highlighting the company's growth prospects.
Hims & Hers Health also added nearly 155,000 new users, bringing its total subscriber count to 1.9 million. The company's entry into the compounded GLP-1 space, a class of drugs, has been a significant factor in its recent developments. Despite some volatility, Needham believes this move will positively influence the company's fundamental profile and contribute to its growth trajectory.
Looking ahead, Hims & Hers Health has projected its 2024 revenue to be between $1.37 billion and $1.4 billion, with an adjusted EBITDA between $140 million and $155 million. The company also aims to have over 1 million personalized subscriptions by year-end. These projections underscore the company's ongoing commitment to growth and expansion in the digital healthcare industry.
InvestingPro Insights
Amidst the recent transactions by Hims & Hers Health, Inc. CEO Andrew Dudum, InvestingPro data and tips provide a broader financial context to the company's current market position. With a market capitalization of approximately $3.14 billion, Hims & Hers Health appears to maintain a strong presence in the market. The company's aggressive share buyback strategy, as indicated by an InvestingPro Tip, suggests management's confidence in the company's value. Furthermore, the expectation of net income growth this year aligns with a positive outlook for the company's financial performance.
InvestingPro Data also reveals a significant P/E ratio of 169.41, which, although high, might reflect investors' high expectations for the company's future earnings. The company's revenue has shown impressive growth over the last twelve months, with an increase of 50.15%, indicating a robust expansion in its business operations. However, the company's stock has experienced some volatility, with a 1-month price total return showing a decrease of 18.11%. This could be a point of consideration for investors looking at the short-term performance.
InvestingPro Tips further highlight that three analysts have revised their earnings upwards for the upcoming period, which may offer investors additional confidence in the company's potential for growth. Additionally, it is worth noting that the company does not pay a dividend, which could be a factor for income-focused investors. For those interested in further insights, there are 15 additional InvestingPro Tips available, offering a comprehensive analysis of Hims & Hers Health's financial health and stock performance.
Overall, the financial data and InvestingPro Tips provide a nuanced understanding of Hims & Hers Health's market dynamics, which may be valuable for investors considering the implications of the CEO's recent stock transactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.